Matthew Squires

Matthew Squires

UNVERIFIED PROFILE

Are you Matthew Squires?   Register this Author

Register author
Matthew Squires

Matthew Squires

Publications by authors named "Matthew Squires"

Are you Matthew Squires?   Register this Author

22Publications

585Reads

39Profile Views

Static beam tomotherapy as an optimisation method in whole-breast radiation therapy (WBRT).

J Med Radiat Sci 2017 Dec 4;64(4):281-289. Epub 2017 Jun 4.

Radiation Oncology Centres, Wahroonga, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmrs.232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715293PMC
December 2017

Towards High Accuracy Reflectometry for Extreme-Ultraviolet Lithography.

J Res Natl Inst Stand Technol 2003 Jul-Aug;108(4):267-73. Epub 2003 Aug 1.

National Institute of Standards and Technology, Gaithersburg, MD, 20899-8410 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6028/jres.108.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846234PMC
July 2016

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Br J Haematol 2016 06 25;173(6):938-40. Epub 2015 Aug 25.

Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13644DOI Listing
June 2016

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Clin Cancer Res 2014 Jun 1;20(11):3012-22. Epub 2014 Apr 1.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France; Medizinische Hochschule Hannover, Hannover; Technische Universität München, Munich, Germany; Taichung Veterans General Hospital, National Yang-Ming University School of Medicine; National Taiwan University Hospital, Taipei, Taiwan; 12 de Octubre University Hospital, Madrid, Spain; University of California, San Francisco, San Francisco, California; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3006DOI Listing
June 2014

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

Int J Cancer 2012 Jun 19;130(12):2997-3005. Epub 2011 Nov 19.

Arizona Cancer Center, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.26324DOI Listing
June 2012

Atom chips on direct bonded copper substrates.

Rev Sci Instrum 2011 Feb;82(2):023101

Air Force Research Laboratory, Hanscom AFB, Massachusetts 01731, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.3529434DOI Listing
February 2011

AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.

Mol Cancer Ther 2010 Apr 30;9(4):920-8. Epub 2010 Mar 30.

Astex Therapeutics Ltd, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-09-1071DOI Listing
April 2010

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.

Mol Cancer Ther 2009 Feb 27;8(2):324-32. Epub 2009 Jan 27.

Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0890DOI Listing
February 2009

DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.

Cell Signal 2008 May 27;20(5):836-43. Epub 2007 Dec 27.

Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2007.12.014DOI Listing
May 2008

Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Biochem J 2002 Sep;366(Pt 2):673-80

Signalling Programme, The Babraham Institute, Babraham Hall, Cambridge CB2 4AT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20020372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222809PMC
September 2002